If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful. There can be no assurance that we will generate adequate funds to continue development, or will ever achieve significant revenues or profitable operations. Many factors (e.g. competition, patent protection, appropriate regulatory approvals) can influence the revenue and product profitability potential.
In developing a pharmaceutical product, we rely upon our employees, contractors, consultants and collaborators and other third party relationships, including our ability to obtain appropriate product liability insurance. There can be no assurance that these reliances and relationships will continue as required.
In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress being made by Oncolytics.
See also "RISK FACTORS AFFECTING FUTURE PERFORMANCE" in our 2006 MD&A.
REOLYSIN(R) Development Update for the Third Quarter of 2007
We continue to develop our lead product REOLYSIN(R) as a possible cancer therapy. Our goal each year is to advance REOLYSIN(R) through the various steps and stages of development required for potential pharmaceutical products. In order to achieve this goal, we actively manage the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and REOLYSIN(R) supply, and our intellectual property.
Clinical Trial Program
Our clinical trial program includes eight clinical trials of which
seven are being conducted by us and one is being sponsored by the U.S.
National Cancer Institute ("NCI"). In the third quarter of 2007, we
announced positive int
|SOURCE Oncolytics Biotech Inc.|
Copyright©2007 PR Newswire.
All rights reserved